Weighing effectiveness versus risk in obesity drugs - southflorida.com
Links shared publicly online about this topic.
- 658total visits
Weighing effectiveness versus risk in obesity drugs - southflorida.com
southflorida.sun-sentinel.com —
View full resource at southflorida.sun-sentinel.com
Tags: Obesity, Obesity Medication, Drug, FDA, Qnexa, Contrave, Doctor
Most Recently Shared on December 13, 2010 at 9:41 am By:
Weighing effectiveness versus risk in obesity drugs: As drug after drug falters or falls by the wayside, doctors... http://bit.ly/gBhaGY
Weighing effectiveness versus risk in obesity drugs - latimes.com
latimes.com — “FDA advisory panels have recently recommended against approving Lorqess and Qnexa, and Meridia is off the market. Contrave may be approved. Obesity experts say the agency may be too stringent.” View full resource at latimes.com
Most Recently Shared on December 13, 2010 at 5:29 pm By:
Weighing effectiveness versus risk in obesity drugs http://lat.ms/f9EUG6
Weighing effectiveness versus risk in obesity drugs - Health Key
healthkey.com — “FDA advisory panels have recently recommended against approving Lorqess and Qnexa, and Meridia is off the market. Contrave may be approved. Obesity experts say the agency may be too stringent.” View full resource at healthkey.com
Most Recently Shared on December 13, 2010 at 3:45 pm By:
Hisham Rana, MD Doctor and Physician
Column: Weighing effectiveness versus risk in #obesity drugs http://bit.ly/g6eHpw - #health
Weighing effectiveness versus risk in obesity drugs - latimes.com
latimes.com — “FDA advisory panels have recently recommended against approving Lorqess and Qnexa, and Meridia is off the market. Contrave may be approved. Obesity experts say the agency may be too stringent.” View full resource at latimes.com
Most Recently Shared on December 11, 2010 at 9:38 pm By:
Weighing effectiveness versus risk in obesity drugs: Experts disagree on whether the FDA is too tough or not tou... http://lat.ms/h93Pet
Weighing effectiveness versus risk in obesity drugs - latimes.com
latimes.com — “FDA advisory panels have recently recommended against approving Lorqess and Qnexa, and Meridia is off the market. Contrave may be approved. Obesity experts say the agency may be too stringent.” View full resource at latimes.com
Most Recently Shared on December 11, 2010 at 9:31 pm By:
LA Times Health News Health News
Weighing effectiveness versus risk in obesity drugs http://lat.ms/hWnx6c
Weighing effectiveness versus risk in obesity drugs - QualityPoint Technologies
qualitypointtech.net — “Experts disagree on whether the FDA is too tough or not tough enough on weight-loss medications.In their quest to find drugs to curb obesity, scientists have had about as much success as long-term dieters who want to stay thin — which is to say, very little. In fact, the last year has been so bleak on the research front that some experts are questioning whether a long-desired safe and effective diet pill can be found. (Source: L.A. Times - Health)MedWorm Sponsor Message: Watch the new MedW” View full resource at qualitypointtech.net
Most Recently Shared on December 11, 2010 at 7:48 pm By:
Weighing effectiveness versus risk in obesity drugs: Experts disagree on whether the FDA is too tough or not tough... http://bit.ly/fpt6CU
Advertisement
